Vincenzo De Giorgi
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (21)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Periocular sebaceous carcinoma (PSC) is a rare, aggressive, and potentially metastatic adnexal malignancy. Due to the ability of PSC to resemble several benign and malignant conditions, diagnosis is often delayed or mistaken. In addition, even with a known diagnosis, choosing the right treatment is still an open debate. For this reason, we decided to review the most up‐to‐date literature on PSC and propose a dedicated procedural protocol to help clinicians when dealing with PSC. A PubMed search was carried out using the terms “Sebaceous Carcinoma”, “Adnexal Periocular Cancer”, “Sebaceous Carcinoma AND eyelid”, “Periocular Sebaceous Carcinoma”, and “Ocular Adnexa”. Pertinent studies published in English from 1997 up to December 2022 were compared to the selection criteria and if suitable, included in this review. Through the initial search, 84 articles were selected. Of these, 36 were included in the final study. Several papers explored different diagnostic and therapeutic strategies regarding PSC diagnosis and management. In light of the current literature review and the multidisciplinary experience of three clinical centers, a dedicated procedural protocol is proposed. PSC diagnosis may be achieved through accurate clinical evaluation, but it requires histopathologic confirmation, which can be challenging. Dermoscopy, in vivo reflectance confocal microscopy, and optical coherence tomography may facilitate PSC clinical examination, while immunohistochemistry stains may support histological diagnosis. Appropriate disease staging is necessary before choosing the treatment, as local disease requires radically different treatment compared to advanced disease. In addition, recent innovations in nonsurgical treatments, including radio‐chemotherapy, immunotherapy, and targeted therapy, may be a viable option in the most challenging cases.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (9)
Maria Antonietta Pizzichetta
Associate Professor of Dermatology
Università degli Studi di Torino
FEDERICA SCARFÌ
University of Florence
Giuseppe Palmieri
Professore Ordinario di Oncologia Medica
Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia
Federico Venturi
University of Bologna
Daniela Massi
Prof. at University of Florence
University of Florence
davide melandri
University of Bologna
Piero Covarelli
University of Perugia
Luca Stingeni
-
Elisabetta Magnaterra
-
Make your next move.
Prepare your application
Review drafts before you send them.